EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds discussed on this page are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Browse by Condition
Age-Related Cognitive Decline
Cognitive decline is one of the most feared consequences of aging—and one where peptide research is generating genuine scientific interest alongside genuine frustration. Twelve compounds on Peptidings have published research relevant to neuroprotection, cognitive enhancement, or neurodegenerative disease. Two have failed pivotal trials (Cerebrolysin’s FDA strategy, Davunetide). Several have intriguing preclinical data and Russian or Khavinson clinical histories that defy easy categorization.
The evidence tiers on this page tell a sobering story. No compound here has achieved Western regulatory approval specifically for cognitive decline. The closest—Cerebrolysin—is approved in dozens of countries outside the US but failed its FDA registration strategy. The pipeline is active but littered with expensive failures.
Condition at a Glance
|
12 Compounds Researched |
0 FDA Approved for Cognition |
2 Clinical Trials |
4 Pilot Data |
6 Preclinical / Complicated |
|
Clinical Trials Human clinical trial data (Phase I+) |
Pilot / Limited Human Data Small or preliminary human studies |
Preclinical Only Animal models and cell culture only |
It’s Complicated Mixed evidence or classification issues |
BLUF: Bottom Line Up Front
No FDA-approved cognitive peptides. Cerebrolysin has the most data—approved in 40+ countries, used in millions of patients—but its FDA-strategy failures and mixed Cochrane review results limit Western credibility. Semax and Selank are Russian-approved nootropics with real clinical data but zero Western replication. Davunetide failed its Phase 2/3 PSP trial definitively. Dihexa, P21, PE-22-28, and PACAP are preclinical-only with dramatic rodent results and zero human data for cognition. Pinealon is a Khavinson bioregulator with a long Russian clinical tradition but no controlled Western trials. Methylene Blue is not a peptide but has more cognitive clinical data than most entries here.
Compounds Researched for This Condition
12 compounds with published research relevant to age-related cognitive decline. Evidence tiers reflect the strength of research for this specific condition—not the compound’s highest overall tier.
Group 1 of 4
The Most-Studied
Two compounds with the most extensive clinical data for neurological conditions—one internationally approved, one that failed its pivotal trial.
Group 2 of 4
The Russian & Khavinson Traditions
Four peptides with Russian regulatory approval or Khavinson bioregulator origins—real data from different evidence traditions, with zero Western replication.
|
|
|
||||||||||||
|
Group 3 of 4
The Preclinical Frontier
Compounds with dramatic rodent data and zero human evidence for cognitive enhancement.
|
|
|
||||||||||||
|
Group 4 of 4
The Outliers
Compounds with cognitive research that do not fit neatly into the peptide framework.
|
|
What the Research Landscape Looks Like
Cognitive decline is the condition where peptide research is most humbling. The preclinical data is extraordinary—Dihexa’s synaptogenic potency, P21’s adult neurogenesis, PACAP’s broad neuroprotection, Semax’s BDNF upregulation—but the clinical translation gap is wider here than in any other condition on Peptidings. The two compounds that reached pivotal trials (Cerebrolysin, Davunetide) produced ambiguous-to-negative results. The compounds with the most dramatic mechanistic data (Dihexa, P21, PE-22-28, PACAP) have never been tested for cognitive endpoints in a single human.
The Russian nootropics (Semax, Selank, Cortexin) and the Khavinson bioregulator Pinealon occupy an uncomfortable middle ground. They have real clinical data or clinical traditions, real patient populations, and in some cases real regulatory approval—but from evidence traditions that Western regulatory bodies do not accept at face value. Whether that skepticism is warranted scientific rigor or institutional bias depends on whom you ask.
| Mechanism | Compounds |
|
Neurotrophic Factor Enhancement Increasing BDNF, NGF, or other growth factors that support neuron survival, synaptic plasticity, and memory formation. |
Cerebrolysin, Semax, Dihexa, P21, PACAP |
|
Microtubule Stabilization Protecting the intracellular transport system that neurons depend on for axonal function—relevant to tauopathies and Alzheimer's. |
NAP (Davunetide) |
|
GABAergic / Anxiolytic Modulation Modulating GABA and serotonin systems to reduce anxiety and improve cognitive performance under stress. |
Selank, DSIP |
|
Pineal & Bioregulator Signaling Acting on the pineal-hypothalamic axis and short-peptide signaling claimed to restore age-related regulatory balance. |
Pinealon |
|
Mitochondrial / Metabolic Enhancement Improving neuronal energy metabolism to support cognitive function during aging. |
Methylene Blue |
Plain English
The brain is the hardest organ to treat with peptides—the blood-brain barrier keeps most molecules out, and cognitive decline involves complex, poorly understood processes. The most-studied compounds here have either mixed results (Cerebrolysin) or definitive failures (Davunetide). The most exciting preclinical compounds (Dihexa, P21, PE-22-28, PACAP) have never been tested in humans for cognitive endpoints. The Russian nootropics (Semax, Selank, Cortexin) and the Khavinson bioregulator Pinealon have real clinical use or tradition but Western regulators don’t accept the data at face value. This is the most honest and humbling conditions page on the site.
Related Research
Research Clusters Covering These Compounds
|
Cognitive & Neuroprotective Peptides The primary cluster—nootropics, neurotrophics, and neuroprotective agents. |
Khavinson Bioregulator Peptides Home cluster for Pinealon and the Khavinson short-peptide longevity family. |
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.